Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
43 studies found for:    daratumumab | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Daratumumab in Treating Patients With Multiple Myeloma
Condition: Plasma Cell Myeloma
Intervention: Biological: Daratumumab
2 Recruiting Daratumumab for the Treatment of Patients With AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: daratumumab
3 Not yet recruiting Daratumumab in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Hematopoietic/Lymphoid Cancer;   Acute Myelogenous Leukemia;   High-Risk Myelodysplastic Syndrome
Intervention: Drug: Daratumumab
4 Not yet recruiting Daratumumab in Treatment of PGNIMD and C3 GN
Condition: Membranoproliferative Glomerulonephritis
Intervention: Drug: Daratumumab
5 Recruiting A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Atezolizumab;   Drug: Daratumumab
6 Recruiting An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Conditions: Lymphoma, Mantle-Cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular
Intervention: Drug: Daratumumab
7 Not yet recruiting Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
Condition: Relapse and / or Refractory Myeloma
Intervention: Drug: Daratumumab, thalidomide and dexamethasone
8 Recruiting A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
Condition: Lymphoma
Intervention: Drug: Daratumumab
9 Recruiting Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Bortezomib;   Drug: Dexamethasone
10 Recruiting Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Daratumumab
11 Recruiting A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab Subcutaneous (SC) Administration;   Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC infusion
12 Recruiting Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
Condition: Multiple Myeloma
Intervention: Drug: Daratumumab
13 Recruiting Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Dexamethasone
14 Recruiting A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab (16 mg/kg);   Drug: Lenalidomide;   Drug: Dexamethasone
15 Recruiting "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Lenalidomide;   Drug: Dexamethasone
16 Available Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Daratumumab
17 Recruiting Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Condition: Myelodysplastic Syndromes
Interventions: Drug: Talacotuzumab;   Drug: Daratumumab
18 Recruiting A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD);   Drug: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab;   Drug: Daratumumab
19 Recruiting Daratumumab in Combination With ATRA
Condition: Multiple Myeloma
Intervention: Drug: all-trans retinoic acid (ATRA)
20 Recruiting Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Lenalidomide;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.